Maven Securities LTD Protagonist Therapeutics, Inc Transaction History

Maven Securities LTD

  • $585 Million
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$7.06 - $25.52 $139,082 - $502,744
-19,700 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$23.34 - $36.08 $459,798 - $710,776
19,700 New
19,700 $466,000
Q1 2021

May 17, 2021
SELL
$19.02 - $31.15 $1.71 Million - $2.8 Million
-90,000 Closed
0 $0
Q4 2020

Feb 12, 2021
BUY
$18.49 - $25.13 $1.66 Million - $2.26 Million
90,000 New
90,000 $1.81 Million

Others Institutions Holding PTGX

# of Institutions
195
Shares Held
58.7M
Call Options Held
20.8K
Put Options Held
109K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.19B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email